Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

iwCLL 2025

The biennial International Workshop on Chronic Lymphocytic Leukemia (XXI iwCLL 2025)

12–15 September 2025 | Krakow, Poland

The biennial International Workshop on Chronic Lymphocytic Leukemia^TM (XXI iwCLL 2025) was held in Krakow, Poland, from September 12-15, 2025, and was an opportunity for international leaders and scientists to discuss the latest updates in the pathobiology and treatment of CLL.

View all videos

The SOUNDTRACK-E trial: investigating AZD0486 in CLL, MCL, and DLBCL

Matthew Davids • 13 Sep 2025

Epcoritamab monotherapy in first-line Richter’s transformation: 2-year follow-up of EPCORE CLL-1

Barbara Eichhorst • 14 Sep 2025

Comparing zanubrutinib to AV in CLL: a MAIC of fit patients in SEQUOIA versus patients in AMPLIFY

Mazyar Shadman • 13 Sep 2025

Factors affecting the dose of ibrutinib administered to patients with CLL

Inga Mandac-Smoljanovic • 14 Sep 2025

The BRUIN CLL-321 trial: a Phase III trial of pirtobrutinib in covalent BTKi-exposed CLL/SLL

Marta Coscia • 13 Sep 2025

The optimal duration of time-limited BTKi plus BCL2i combination therapies in CLL

Moritz Fürstenau • 13 Sep 2025

The management of double-refractory CLL: current options and approaches being explored

Kerry Rogers • 13 Sep 2025

MRD-driven venetoclax plus rituximab in previously untreated CLL: the VERITA-PALG-CLL5 trial

Krzysztof Jamroziak • 23 Sep 2025

Advice for community physicians managing patients with CLL

Alexey Danilov • 13 Sep 2025

Managing patients with CLL who relapse after triplet therapy

Jacob Soumerai • 18 Sep 2025

Safety and efficacy of var-cel (ARI-0001) in patients with R/R CLL and Richter’s transformation

Nil Albiol • 13 Sep 2025

Strategies being explored to enhance the metabolic function of T-cells in CLL

Helga Simon-Molas • 13 Sep 2025